By Olokuta Rofiat
The World Health Organization (WHO), has approved the global use of lenacapavir, a twice-yearly injectable drug for HIV prevention, marking a major breakthrough in the fight against the virus.
Announced on July 15, 2025, the approval paves the way for immediate international rollout of the long-acting antiretroviral, developed by Gilead Sciences.
Lenacapavir, administered just once every six months, has shown high efficacy in preventing HIV infections, particularly among high-risk groups, including women and girls in sub-Saharan Africa, where nearly 60% of new cases occur.
Describing the move as a “game-changer,” Dr. Meg Doherty, WHO Director of Global HIV, Hepatitis, and STI Programmes, said the drug offers more flexibility and privacy, addressing challenges like stigma and pill fatigue.
“This twice-a-year option gives people more control over their health,” she noted.
WHO is recommending lenacapavir be included in national HIV prevention strategies alongside existing options like daily oral PrEP and monthly vaginal rings, giving countries more tools to curb new infections.
While the news has been welcomed by health advocates, they are also calling for affordable pricing, widespread public education, and equitable access, especially in low- and middle-income countries that bear the brunt of the epidemic.
Nigeria, for instance, has over 1.8 million people living with HIV, with prevention remaining a significant challenge.
Pending regulatory approvals, lenacapavir is expected to become available in selected countries by late 2025 or early 2026.
With WHO’s endorsement, experts say the drug offers new hope for millions and could significantly reduce global HIV transmission if supported by strong political will and robust healthcare systems.
